Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2012 Jan 24;109(4):999-1000.
doi: 10.1073/pnas.1120993109. Epub 2012 Jan 17.

Reorienting our view of particle-based adjuvants for subunit vaccines

Steven R Little  1
Affiliations
Comment

Reorienting our view of particle-based adjuvants for subunit vaccines

Steven R Little. Proc Natl Acad Sci U S A. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The author declares no conflict of interest.

Figures

Fig. 1.
Fig. 1.
Multivalent display of antigen and TLR4 agonist to an antigen presenting cell (APC) such as a B cell by a malarial sporozoite and a nanoparticle/adjuvant formulation. (A) P. vivax displays circumsporozoite proteins (CSP) prominently on its surface, as well as structures that likely serve as TLR4 agonists (12, 13). Clustering of B-cell receptors is achieved as a result of the natural, repetitive display of the CSP. This combination of persistent, multivalent antigen presentation in context with particular, parasite-associated “danger signals” would be recognized by the immune system in a way that would produce immune responses that are well-suited to combat the parasite. (B) Synthetic ICMVs [as described in PNAS (4)] can be designed to display a subunit CSP antigen (VMP001) through both sustained release and multivalent presentation on their surface. When administered along with the TLR4 agonist MPLA, these nanoparticles produce an immune response that is better suited to combat malaria than when antigen and conventional adjuvant are delivered alone.
See this image and copyright information in PMC

Comment on

References

    1. Price RN, Douglas NM, Anstey NM. New developments in Plasmodium vivax malaria: Severe disease and the rise of chloroquine resistance. Curr Opin Infect Dis. 2009;22:430–435. - PubMed
    1. Bell BA, et al. Process development for the production of an E. coli produced clinical grade recombinant malaria vaccine for Plasmodium vivax. Vaccine. 2009;27:1448–1453. - PubMed
    1. Coffman RL, Sher A, Seder RA. Vaccine adjuvants: Putting innate immunity to work. Immunity. 2010;33:492–503. - PMC - PubMed
    1. Moon JJ, et al. Enhancing humoral responses to a malaria antigen with nanoparticle vaccines that expand Tfh cells and promote germinal center induction. Proc Natl Acad Sci USA. 2012;109:1080–1085. - PMC - PubMed
    1. Hirosue S, Kourtis IC, van der Vlies AJ, Hubbell JA, Swartz MA. Antigen delivery to dendritic cells by poly(propylene sulfide) nanoparticles with disulfide conjugated peptides: Cross-presentation and T cell activation. Vaccine. 2010;28:7897–7906. - PubMed

Publication types

MeSH terms

LinkOut - more resources